Evaluation of appropriateness of inhaled corticosteroid (ICS) therapy in COPD and guidance on ICS withdrawal

This guide provides an algorithm to identify people with chronic obstructive pulmonary disease (COPD) who might benefit from ICS treatment and those in whom it may not be appropriate, and an approach to withdrawing ICS in patients in whom it is not needed.

- In patients with COPD at low risk of exacerbation, bronchodilation should be the first-line treatment. [GOLD 2017]. In symptomatic patients on monotherapy, treatment can be stepped up to a combination long-acting β2-agonist plus long acting muscarinic antagonist (LABA+LAMA), and for patients with severe breathlessness (CAT score 10 or MRC grade 2) initial therapy with LABA+LAMA may be considered [GOLD 2017].
- In patients at high risk of an exacerbation or fewer symptoms (CAT score <10 or MRC grade <2),



For people with COPD who don't need ICS

Remove ICS or switch to lower-dose ICS in separate inhaler

- Low/Medium-dose* ICS → stop ICS; Switch to LABA/LAMA (optimised bronchodilation)
- High-dose* ICS → switch to lower-dose* ICS in separate inhaler#; In combination with LABA/LAMA (optimised bronchodilation)

4 weeks

Interim call with patient (approx. 2 weeks) to check compliance and ensure stability

Consultation with monitoring clinician including assessment of pulmonary function using spirometry

- If stable or improved: continue with LABA/LAMA (optimised bronchodilation)
- If stable or improved: continue with LABA/LAMA (optimised bronchodilation); stop ICS in separate inhaler

4 weeks

Patient should be encouraged to contact monitoring clinician if any worsening of symptoms or conditions

If stable or improved: continue with LABA/LAMA (optimised bronchodilation)

6 months

Reassess need for ICS use if:
- moderate or severe exacerbations
- airflow limitation worsening (FEV_1 decrease ≥100 mL)
- Optional (blood eosinophil count >400)

Follow-up with monitoring clinican for full clinical review

See the patient
- twice yearly during the first year of ICS withdrawal,
- followed by an annual review if the patient's COPD is stable and exacerbation-free

* See next figure # ICS that is not in a combination inhaler is not licenced for treatment of COPD

Note: Whilst the use of LAMA and LABA in combination is recommended as an option by both GOLD and NICE for patients with exacerbations of COPD, this is not a licensed indication

SEE https://goo.gl/fw5o6C FOR MORE INFORMATION ON EOSINOPHILS

the recommended first-line treatment is a LAMA (stepping up to LABA+LAMA if exacerbations persist) or a LABA+ LAMA. In higher risk symptomatic patients, combination LABA+ LAMA is the preferred first-line treatment, with LAMA or ICS+ LABA given as alternative options [GOLD 2017]. If exacerbations persist on LABA+ LAMA, patients can be stepped up to LABA+ LAMA+ICS (triple therapy).

- Long-term ICS use is associated with a significant risk of pneumonia [Yawn 2013; Suissa 2013; Kew & Seniukovich 2014], and systemic effects [Price 2012]; therefore ICS-containing regimens are not recommended in low-risk patients, and should only be considered for high-risk patients with features of asthma, or as triple therapy if exacerbations persist despite treatment with a LABA+LAMA [GOLD 2017].
- Discontinuing ICS rapidly decreases the risk of serious pneumonia [Suissa 2015].
- Despite years of guidance on the limited role of ICS in COPD [GOLD 2001], there is evidence of inappropriate use of ICS in COPD patients who are at low risk of exacerbation [Vestbo 2014; Price 2014].
- Recent studies have indicated that ICS can be withdrawn in both low- and high-risk patients, provided adequate bronchodilator therapy is in place [Rossi 2014a; Rossi 2014b; Magnussen 2014]. Withdrawal of ICS only increased exacerbation rates in patients with both raised eosinophils and a history of frequent exacerbations [Calverley 2016].

ICS dose switch guidance

Commonly prescribed ICS treatments for COPD and recommended ICS in separate inhaler for change in treatment

Current treatment	Switch to
• Fluticasone/salmeterol - 250/50µg 1 puff twice daily	• LABA/LAMA
• Beclomethasone/formoterol - 100/6µg 2 puffs twice daily	• LABA/LAMA
• Fluticasone/vilanterol - 92/22µg 1 puff once daily	• LABA/LAMA
• Budesonide/formoterol - 400/12µg 1 puff twice daily - 200/6µg 2 puffs twice daily	• LABA/LAMA
• Budesonide/formoterol - 400/12µg 2 puffs twice daily	• LABA/LAMA plus - budesonide 200µg 2 puffs twice daily
• Fluticasone/salmeterol - 500/50µg 1 puff twice daily	• LABA/LAMA plus - fluticasone 250µg 1 puff twice daily

The following fixed ICS/LABA combination brands are licensed in COPD: Seretide Accuhaler, AirFluSal Forspiro, Relvar Ellipta, Symbicort, DuoResp Spiromax, FostairMDI and Foster NEXThaler, Fobumix Easyhaler

References

Calverley PM, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters E, Disse B, Finnigan H, Asijee GM, Watz H. Abstract. Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD. *European Respiratory Journal* 2016 48:OA1973; DOI: 10.1183/13993003.congress-2016.OA1973

Global Initiative for Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease NHLBI/WHO Workshop Report 2001

Global Initiative for Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, 2017. http://www.goldcopd.com

Kew KM. Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2014;10(3)

Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, *et al*; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. *N Engl J Med* 2014;**371**(14):1285–94

Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, Bichel K. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. *Int J Chron Obstruct Pulmon Dis* 2014

Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. *Prim Care Respir J* 2012;**22**(1):92–100

Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). *Respir Res* 2014b. 15:77

Rossi A, van der Molen T, del Olmo R, Papi A, Wehbe L, *et al*. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. *Eur Respir J* 2014a;**44**(6):1548–56

Suissa S, Coulombe J, Ernst P. Discontinuation of Inhaled Corticosteroids in COPD and the Risk Reduction of Pneumonia. *Chest* 2015;**148**(5):1177–83

Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. *Thorax* 2013;**68**:1029–36

Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. *Respir Med* 2014;**108**:729–36

Yawn BP, Li Y, Tian H, Zhang J, Arcona S, et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. *Int J Chron Obstruct Pulmon Dis* 2013;**8**:295–304

Adapted, with permission from the International Primary Care Respiratory Group (IPCRG). January 2018. The PCRS-UK wish to acknowledge and thank IPCRG for allowing PCRS-UK to adapt this material specifically for UK use based on current national guidance. This resource is advisory; it is intended for general use and should not be regarded as applicable to a specific case. This resource has been adapted by Dr Noel Baxter, Dr Kevin Gruffydd-Jones, Dr Vince Mak and Dr Iain Small. The online version of this document can be downloaded from https://pcrs-uk.org/stepping-down-ics-copd

The original IPCRG version of the desktop helper was written by Dr Alan G Kaplan, Dr Miguel Román Rodríguez, Professor David B Price and Dr Ioanna Tsiligianni and can be obtained from https://goo.gl/AB713K

The Primary Care Respiratory Society, is a registered charity; (Charity No: 1098117) and a company limited by guarantee registered in England (Company No: 4298947). VAT Registration Number: 866 1543 09. Registered offices: PCRS-UK, Miria House, 1683b High Street, Knowle, Solihull B93 0LL. Telephone: +44 (0)1675 477600. Email: info@pcrs-uk.org Website: http://www.pcrs-uk.org Twitter: @pcrsuk Facebook: https://www.facebook.com/PCRSUK

The Primary Care Respiratory Society UK is grateful to its corporate supporters including AstraZeneca UK Ltd, Boehringer Ingelheim Ltd, Chiesi Ltd, Johnson & Johnson Ltd, Napp Pharmaceuticals, Novartis UK, Pfizer Ltd. and TEVA UK Limited for their financial support which supports the core activities of the Charity and allows PCRS-UK to make its services either freely available or at greatly reduced rates to its members.